TellBio

Executive Summary

TellBio Inc. is a development-stage biotechnology company headquartered in Cambridge, MA, founded in 2020 with a mission to revolutionize cancer detection and treatment. The company leverages its proprietary circulating tumor cell (CTC) technology through two complementary platforms: TellDx, a diagnostic tool for early cancer detection and monitoring, and TellRx, a therapeutic platform designed to target CTCs and prevent metastasis. By focusing on CTCs—the 'seeds' of metastatic spread—TellBio aims to address a critical unmet need in oncology, potentially enabling earlier intervention and more personalized treatment strategies. The company is privately held and has not yet disclosed total funding or valuation, indicating it is likely in early stages of development and seeking initial capital or partnerships to advance its platforms.

Upcoming Catalysts (preview)

• Q3 2026Series A or Seed Funding Round Announcement70% success
• 2027Partnership with Major Pharma or Diagnostics Company40% success
• TBDInitial Clinical Data from TellDx or TellRx Platform30% success